A new mRNA melanoma vaccine from Merck and Moderna showed sustained benefits over five years, cutting the risk of cancer ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...

An experimental vaccine from Moderna shows promise in keeping deadly skin cancer from returning for years, according to new ...

Study results released on Monday revealed that a personalized mRNA vaccine manufactured by Moderna and Merck has shown ...

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...

A personalized mRNA melanoma vaccine combined with immunotherapy reduced cancer recurrence and improved survival in high-risk ...

A 19-year-old boy is recalling being diagnosed with stage 3 melanoma at the age of 15, and how doctors initially dismissed one of his symptoms as a sign of "puberty." Samuel Gee told Today.com that he ...

Distinct effect of neoadjuvant PD1 alone, PD1+IPI, and PD1+lenvatinib in the peripheral immune profile of melanoma patients (pts) and correlation with pathological (path) response. Combining machine ...

Opdivo and Yervoy improve cure rates in resected stage 3/4 melanoma compared to placebo, with Opdivo showing superior efficacy. CheckMate 238 and EORTC 18071 trials reveal Opdivo's cure rate advantage ...

Stage III melanoma carries a high risk of regional relapse and distant metastasis despite complete surgical resection. Neoadjuvant immunotherapy—administered prior to definitive surgery—aims to reduce ...

Adjuvant treatment following resection of stage III melanoma is standard practice, based largely on trials that showed it improves recurrence-free survival. However, oncologists have long wondered ...